Business Wire

FOURKITES

22.11.2021 10:02:08 CET | Business Wire | Press release

Share
New Research from FourKites and Reuters Highlights Massive Challenges Facing European Supply Chains

To better understand the state of European supply chains, FourKites® , the #1 real-time supply chain visibility platform, partnered with Reuters Events to survey over 450 supply chain leaders across the continent, with particular emphasis on the United Kingdom, Germany and the Netherlands. The responses represent a broad perspective of the concerns and challenges surrounding European supply chains, sustainability and the role of real-time visibility in streamlining operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122005011/en/

Coming in the midst of ongoing disruptions caused by COVID-19, State of the European Supply Chain: Logistics, Sustainability and Visibility Report 2022 reveals that the demand shock, labour shortages, port disruptions and capacity constraints have accelerated the adoption of supply chain visibility solutions throughout Europe. However, while many companies have adopted new digital practices, more than 60% of European companies admitted they’re slow to react to changing trends in logistics technologies, according to the report.

Key findings include:

  • Over half of all respondents are currently using supply chain visibility solutions, but one-third (33%) are having trouble improving data-driven processes such as forecasting, receiving operations and labour.
  • The majority of respondents (67%) cited end-to-end freight traceability as their biggest pain point when transporting goods.
  • More than half of respondents (63%) cited carriers providing inaccurate ETAs as a persistent problem.

“If we have visibility, we can be efficient and flexible," said Ferenc Polgar, Global Distribution Operational Excellence Lead at Bayer. "We can communicate delays to our customers so they can adjust their operations and improve their experience. We can be more effective during peak distribution periods to make sure plans are going accordingly.”

“Being able to see your goods in transit is one piece of the puzzle, but it doesn’t help navigate the many disruptions and delays that inevitably take place once the product leaves the ship or warehouse,” said Matt Elenjickal, founder and CEO of FourKites. “For that reason, the paradigm is shifting to full end-to-end supply chain visibility, wherein the goal is total predictive visibility across the entire supply chain, enabling proactive risk management vs. reactive problem-solving.”

Pain points vary between the UK, Germany and the Netherlands

Looking at their three biggest pain points in transporting goods, respondents from the UK, Germany and the Netherlands had surprisingly different answers:

  • The UK was relatively balanced, with 71% of respondents citing end-to-end freight traceability, carrier relationships, and dwell times as their biggest pain points.
  • In the Netherlands, 75% of retailers and manufacturers said their biggest pain point was carrier relationships.
  • In Germany, 100% of respondents were struggling with ensuring end-to-end freight traceability.

Overall, respondents indicated supply chain visibility improved their planning and inventory management (60%), customer service (56%) and increased efficiency (38%). In the Netherlands, 40% saw an improvement to customer service whereas in Germany that number was even higher at 100%. Meanwhile, in the UK 63% said that improved planning and inventory management is the primary benefit of visibility.

Even the most commonly used mode of transportation also varied widely across the continent: 63% of UK respondents cited full truckload as their key mode of freight, while 80% of Netherlands respondents are using less than truckload, and 100% of German respondents are transporting freight by air, both domestically and internationally.

Sustainability is a priority, but not without challenges

The survey illustrates that sustainability is top of mind for today’s supply chain leaders. Over 80% indicated that they were either holding steady (44%) or increasing (40%) their commitment to sustainability, emphasising the urgency with which businesses understand they are required to act.

The two key supply chain sustainability goals articulated by respondents were the reduction of carbon emissions in transportation (39%) and manufacturing (31%), as well as the reduction of non-renewable packaging materials (31%). However, over a quarter of respondents also reported mapping sustainability impact throughout their supply chain as a challenge to modernising transportation assets.

"We use supply chain visibility data to understand better where there's waste within the supply chain. Where do we have excessive empty miles?" said Paul Avampato, Head of International Logistics at Henkel. "We believe by reducing dwell time that we can keep the network moving smoother. The more we reduce dwell time, the less trucks that you have to put on the road."

Read the full report here .

About FourKites

FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 750 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye